TICKERNOMICS Sign up
Last Update: 2024-12-27 15:27:40
Acumen Pharmaceuticals Inc. ( ABOS ) https://acumenpharm.com
1.89USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-50.65%
ABOS
SPY
32.66%
-71.58%
ABOS
SPY
108.59%
ABOS
0.00%
SPY
302.52%
ABOS
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
107.54
-92.49
0.68
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-1.32
76.98
0.50
-45.94
0.00
0.87
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-6128.97
-15.17
-9181.55
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
-80.55
-43.91
0.00
Other Earnings and Cash Flow Stats:
Acumen Pharmaceuticals Inc. ( ABOS ) Net Income TTM ($MM) is -81.67
Acumen Pharmaceuticals Inc. ( ABOS ) Operating Income TTM ($MM) is -92.91
Acumen Pharmaceuticals Inc. ( ABOS ) Owners' Earnings Annual ($MM) is 0.00
Acumen Pharmaceuticals Inc. ( ABOS ) Current Price to Owners' Earnings ratio is 0.00
Acumen Pharmaceuticals Inc. ( ABOS ) EBITDA TTM ($MM) is -92.73
Acumen Pharmaceuticals Inc. ( ABOS ) EBITDA Margin is -9181.55%
Capital Allocation:
Acumen Pharmaceuticals Inc. ( ABOS ) has paid 0.00 dividends per share and bought back -5.850148 million shares in the past 12 months
Acumen Pharmaceuticals Inc. ( ABOS ) has increased its debt by 0.314 million USD in the last 12 months
Capital Structure:
Acumen Pharmaceuticals Inc. ( ABOS ) Interest-bearing Debt ($MM) as of last quarter is 0
Acumen Pharmaceuticals Inc. ( ABOS ) Annual Working Capital Investments ($MM) are 51
Acumen Pharmaceuticals Inc. ( ABOS ) Book Value ($MM) as of last quarter is 217
Acumen Pharmaceuticals Inc. ( ABOS ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Acumen Pharmaceuticals Inc. ( ABOS ) has 33 million in cash on hand as of last quarter
Acumen Pharmaceuticals Inc. ( ABOS ) has 19 million of liabilities due within 12 months, and long term debt 27 as of last quarter
Acumen Pharmaceuticals Inc. ( ABOS ) has 60 common shares outstanding as of last quarter
Acumen Pharmaceuticals Inc. ( ABOS ) has 0 million USD of preferred stock value
Academic Scores:
Acumen Pharmaceuticals Inc. ( ABOS ) Altman Z-Score is -0.68 as of last quarter
Acumen Pharmaceuticals Inc. ( ABOS ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Acumen Pharmaceuticals Inc. ( ABOS ) largest shareholder is owning shares at 0.00 ($MM) value
Derek M Meisner(an insider) Sold 8933 shares of Acumen Pharmaceuticals Inc. ( ABOS ) for the amount of $31086.84 on 2024-01-19
11.24% of Acumen Pharmaceuticals Inc. ( ABOS ) is held by insiders, and 78.46% is held by institutions
Acumen Pharmaceuticals Inc. ( ABOS ) went public on 2021-07-01
Other Acumen Pharmaceuticals Inc. ( ABOS ) financial metrics:
FCF:-67.35
Unlevered Free Cash Flow:254.59
EPS:-1.98
Operating Margin:-6128.97
Gross Profit Margin:-15.17
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-54.82
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Acumen Pharmaceuticals Inc. ( ABOS ) :
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.